Personalis, Inc. (PSNL) Stock Price & Analysis
Personalis, Inc. (PSNL) fell 2.89% to USD 9.75 as of June 10, 2026 at 03:13 UTC, according to Nexqual real-time market data.
PSNL last closed at USD 10.04; the session ranged USD 9.08–10.12 on volume of 3,937,363 shares. Market capitalization is $1.02B, with a 52-week range of USD 3.84–12.53 (NGM). Source: Nexqual, June 10, 2026 at 03:13 UTC.
Key Statistics (as of June 10, 2026 at 03:13 UTC)
| Price | USD 9.75 |
|---|---|
| Change | ▼ 2.89% (down) |
| Previous Close | USD 10.04 |
| Open | USD 10.06 |
| Day Range | USD 9.08 – 10.12 |
| 52-Week Range | USD 3.84 – 12.53 |
| Volume | 3,937,363 shares |
| Market Cap | $1.02B |
| Exchange | NGM |
Technical Analysis (PSNL)
Nexqual's technical model rates PSNL "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:13 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.17 (neutral) |
| vs SMA50 | Above (USD 7.29) |
| MACD | 1.11 (positive) |
Analyst Ratings (PSNL)
Wall Street analysts rate PSNL "Strong Buy" based on 7 analysts, with a mean price target of USD 10.86 (range USD 9–13), per Nexqual as of June 10, 2026 at 03:13 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 10.86 |
| High Target | USD 13 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (PSNL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $16.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.29 vs est -0.28 ▼ miss |
| 2025-12-31 | USD -0.26 vs est -0.29 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.27 ▲ beat |
| 2025-06-30 | USD -0.23 vs est -0.24 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financials & Fundamentals (PSNL)
| Total Revenue | $64.52M |
|---|---|
| Revenue Growth (YoY) | -24.90% |
| Gross Margin | +13.72% |
| Operating Margin | -207.87% |
| Profit Margin | -148.11% |
| ROE | -41.35% |
| Debt / Equity | 15.22 |
| Current Ratio | 6.61 |
| Total Cash | $233.22M |
| Total Debt | $38.78M |
| Free Cash Flow | $-42.35M |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financial Health Score (PSNL)
Nexqual rates Personalis, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:13 UTC.
| Growth | Critical — Revenue -18% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $233M cash vs $39M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$42M, burning cash |
| Efficiency | Critical — ROE -41%, ROA -21.4% |
Ownership (PSNL)
| Insider Ownership | +27.05% |
|---|---|
| Institutional Ownership | +70.12% |
| Shares Outstanding | 104.72M |
| Float | 62.43M |
| Short % of Float | +19.34% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Leadership (PSNL)
Personalis, Inc. is led by Christopher M. Hall (age 56), CEO & Director, per Nexqual as of June 10, 2026 at 03:13 UTC.
| CEO & Director | Christopher M. Hall (age 56) |
|---|---|
| Executive VP of R & D, President & Chief Medical Officer | Richard Chen M.D., M.S. (age 54) |
| CFO & COO | Aaron L. Tachibana (age 64) |
| Senior Vice President of Genomic Science | Christian Haudenschild |
| Senior Vice President of Business Development | Stephane Mouradian |
Major Backers & Investors (PSNL)
Notable institutional backers of Personalis, Inc. include ARK Invest, Merck & Co., Inc., Lightspeed Management Company, L.L.C. , according to Nexqual as of June 10, 2026 at 03:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 14.57% |
| Merck & Co., Inc. | 13.41% |
| Lightspeed Management Company, L.L.C. | 7.79% |
| T. Rowe Price | 7.51% |
| Ameriprise Financial, Inc. | 7.25% |
| Aberdeen Group plc | 3.33% |
| Deep Track Capital, Lp | 2.86% |
| AIGH Capital Management LLC | 2.77% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.3% |
| Vanguard Group | 4.83% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
From Personalis, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
- The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
- It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
- In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
| CSTL | Castle Biosciences, Inc. | USD 21.08 | ▲ 0.33% |
| ARCT | Arcturus Therapeutics Holdings | USD 7.16 | ▼ 1.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:13 UTC. This page is informational and not investment advice.